Andrew Fein’s rating is based on several factors that highlight the potential growth and positive impact of ACADIA Pharmaceuticals’ product, Daybue. Despite a slight revenue miss, the patient base for Daybue has shown a steady increase, indicating a promising growth trajectory. Factors contributing to this outlook include a gradual increase in net pricing, reduced discontinuations, and a strategic focus on expanding the patient base. Additionally, the anticipated European launch in 2026 is expected to further enhance market penetration.Real-world feedback from patients and caregivers has been overwhelmingly positive, with reports of improved quality of life, including better motor function, sleep, and overall well-being. These improvements, coupled with increased awareness and diagnosis rates, suggest that Daybue’s sales are on track to continue growing. The combination of these elements supports Fein’s Buy rating for ACADIA Pharmaceuticals, as the company appears well-positioned for future success.
H.C. Wainwright analyst maintained a Buy rating on ACADIA Pharmaceuticals ( – ) today and set a price target of $27.00.
NEU Price at posting:
$12.80 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)